60 Participants Needed

Dexmedetomidine + Midazolam for Pediatric Delirium

AW
RM
KV
AM
Overseen ByArlene M Williams, RN
Age: < 18
Sex: Any
Trial Phase: Phase 4
Sponsor: University of Massachusetts, Worcester
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

Preventing emergent delirium in pediatric ambulatory surgery through preoperative use of intra-nasal Dexmedetomidine and oral Midazolam.

Research Team

RI

R. Ian Richmond, MD

Principal Investigator

University of Massachusetts Chan Medical School

Eligibility Criteria

This trial is for children aged 3 months to 9 years who are scheduled for ear surgery (myringotomy) and are generally healthy (ASA class I-II). It's not for kids over age 9, those with serious heart defects, or non-English speakers without short form consent.

Inclusion Criteria

Children between 3 months and 9 years old.
You are going to have ear surgery to insert ear tubes.
American Society of Anesthesiologists (ASA) classification of I - II.

Exclusion Criteria

You have a heart condition that has not been fixed, including a type called cyanotic congenital heart disease.
Non-English language speaker for whom short form consent is not available
You have a high risk of medical complications according to your health assessment.
See 1 more

Treatment Details

Interventions

  • Dexmedetomidine
  • Midazolam
Trial OverviewThe study tests if using intra-nasal Dexmedetomidine or oral Midazolam before surgery can prevent confusion and agitation (delirium) in kids after they wake up from anesthesia in outpatient ear surgeries.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Intra-nasal DexmedetomidineExperimental Treatment1 Intervention
Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
Group II: Oral MidazolamActive Control1 Intervention
Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.

Dexmedetomidine is already approved in European Union, United States, Canada, Japan for the following indications:

๐Ÿ‡ช๐Ÿ‡บ
Approved in European Union as Precedex for:
  • Sedation in intensive care settings
  • Procedural sedation
๐Ÿ‡บ๐Ÿ‡ธ
Approved in United States as Precedex for:
  • Sedation in intensive care settings
  • Procedural sedation
๐Ÿ‡จ๐Ÿ‡ฆ
Approved in Canada as Precedex for:
  • Sedation in intensive care settings
  • Procedural sedation
๐Ÿ‡ฏ๐Ÿ‡ต
Approved in Japan as Precedex for:
  • Sedation in intensive care settings
  • Procedural sedation

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Massachusetts, Worcester

Lead Sponsor

Trials
372
Recruited
998,000+